Authors: Susan L Uprichard
Publish Date: 2010/07/28
Volume: 25, Issue: 4, Pages: 227-245
Abstract
An estimated 130 million people worldwide are chronically infected with hepatitis C virus HCV making it a leading cause of liver disease worldwide Because the currently available therapy of pegylated interferonalpha and ribavirin is only effective in a subset of patients the development of new HCV antivirals is a healthcare imperative This review discusses the experimental models available for HCV antiviral drug research recent advances in HCV antiviral drug development as well as active research being pursued to facilitate development of new HCVspecific therapeutics
Keywords: